FDA limits use for new Alzheimer's drug after backlash & own experts' resignations over rushed approval — RT USA News
Follow RT on The US Food and Drug Administration has scaled back the prescribed uses for a new Alzheimer’s drug, now limiting it to “mild” dementia cases, after several health advisers resigned in protest over a rushed approval process. Drug developer Biogen announced the new prescribing label on Thursday, noting that aducanumab – also known by its trade name, Aduhelm – should be given only to those in the early stages of Alzheimer’s. “Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population i...